Menu
← Oncology Approval Tracker
FDA DECISION ·
Tibsovo
ivosidenib · Servier Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory myelodysplastic syndromes and a susceptible IDH1 mutation on an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
This use extended IDH1-targeted therapy to a molecularly selected MDS population.
What research teams should watch
Verify the IDH1 result and prior therapy, and plan differentiation syndrome recognition and escalation.
PRIMARY RECORDS